The number of new prescriptions for biosimilar versions of the Humira rheumatoid arthritis treatment increased by 36% in the first week of April, up from 5%, due to CVS Health’s expanding reach in the prescription drug market. This surge was led by the biosimilar Hyrimoz, manufactured by Sandoz, a Novartis unit, and marketed with CVS’s subsidiary, Cordavis. CVS Caremark, a major pharmacy benefit manager, removed Humira from its formularies, causing the spike in Hyrimoz prescriptions. This strategic partnership between CVS and Sandoz has contributed to the success of Hyrimoz in the U.S. market.
Source link
Thanks to CVS, a Humira biosimilar is grabbing huge market share
